A double-blind, randomised, two-way crossover single-centre pharmacokinetic interaction (phase I) study of repeated oral doses of AZ 242 (3 mg) and a single oral dose of warfarin (25 mg) in healthy male subjects
Study identifier:SH-SBC-0015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomised, two-way crossover single-centre pharmacokinetic interaction (phase I) study of repeated oral doses of AZ 242 (3 mg) and a single oral dose of warfarin (25 mg) in healthy male subjects
Medical condition
Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 2003
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
